Mysa Saad/X
Dec 8, 2025, 08:35
Dr. Mysa Saad Had Her First Oral Presentation at ASH25
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on X:
“Congrats to Dr. Mysa Saad on her first oral presentation at ASH25!
Post-hoc AVERT analysis: In cancer patients on apixaban prophylaxis, concurrent antiplatelet/NSAID use ↑ clinically relevant bleeding (HR 1.78) with no VTE benefit.”
Follow the latest in Hemostasis Today.
-
Sep 22, 2026, 16:02Ana Pedrero Gil: Peri-operative Management of Patients Undergoing Day Surgery
-
Sep 22, 2026, 15:27Zia Ullah: RBC-Derived Extracellular Vesicles as Potential Biomarkers of Thrombotic Risk in Dengue
-
Sep 22, 2026, 15:01Lesley Van Wyk: What Each Iron Markers Actually Mean
-
Sep 22, 2026, 14:37Chokri Ben Lamine։ Saudi Arabia Leads A New Milestone In Hemophilia A Care
-
Sep 22, 2026, 13:58Giulia Passaniti: Dual Inferior Vena Cava Anatomy in Tetralogy of Fallot
-
Sep 22, 2026, 13:35Michael Miyamoto: Scaling Guideline Based Lipid Management in Community Practice
-
Sep 22, 2026, 13:15Suvro Sankha Datta: Developing Blood Group Genotyping Platform Using a Gold-Oligo
-
Sep 22, 2026, 13:07Caitlin Raymond: The Plasma Chaser in Therapeutic Plasma Exchange
-
Sep 22, 2026, 09:18Shamee Shastry: How Transfusion Medicine Research Is Evolving in India